Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HO183 CAR T
2025-524876-43-00Phase 3Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing ARI0002h CAR T-cell arm with Standard of care regimen arm (2 arms). Primary endpoint: Progression free survival. Planned start Apr 2026; status: authorised.
02
Drugs
ARI0002h
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2025-524876-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524876-43-00.